EcoDrugPlus

Histone Deacetylase 3

Ensembl ID : ENSXETG00000002708
Gene Symbol: HDAC3
13 Enzyme and pathways 5 View Cross-references
156 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 4

Ensembl ID : ENSXETG00000004880
Gene Symbol: HDAC4
9 Enzyme and pathways 5 View Cross-references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 5

Ensembl ID : ENSXETG00000003365
Gene Symbol: HDAC5
4 Enzyme and pathways 5 View Cross-references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 7

Ensembl ID : ENSXETG00000010661
Gene Symbol: HDAC7
4 Enzyme and pathways 5 View Cross-references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 8

Ensembl ID : ENSXETG00000020527
Gene Symbol: HDAC8
5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 9

Ensembl ID : ENSXETG00000013445
Gene Symbol: HDAC9
5 View Cross-references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hydroxycarboxylic Acid Receptor 2

Ensembl ID : ENSXETG00000033184
Gene Symbol: HCAR2
8 Enzyme and pathways 3 View Cross-references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hydroxysteroid (11-Beta) Dehydrogenase 1-Like, Gene 2

Ensembl ID : ENSXETG00000012212
Gene Symbol: HSD11B1L.2
5 View Cross-references
238 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSXETG00000005192
Gene Symbol: LOC100495521
3 Enzyme and pathways 4 View Cross-references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ileal Sodium/bile Acid Cotransporter

Ensembl ID : ENSXETG00000032246
Gene Symbol: LOC100498575
5 Enzyme and pathways 5 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Beta

Ensembl ID : ENSXETG00000016790
Gene Symbol: IKBKB
46 Enzyme and pathways 5 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSXETG00000044277
Gene Symbol: INPP5D
14 Enzyme and pathways 5 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).